Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Daptomycin

FDA-approved product (powder, intravenous), marketed as Cubicin, Cubicin Rf, Daptomycin and 2 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Daptomycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Bacterial endocarditis
  • Bacteriemia
  • Endocarditis
  • Gram-positive bacterial infections
  • Infection
  • Infective endocarditis
  • Skin disease caused by bacterial infection
  • Soft Tissue Infections

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibacterials
FDA pharmacologic class
Lipopeptide Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01XX09; FDA class Lipopeptide Antibacterial

Repurposing investigation

Daptomycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA98.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
  • E. coli48.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae50.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Daptomycin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Daptomycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock

    NCT02508350 · start 2015-01

    Registered record
    Registry ID
    NCT02508350
    Conditions
    Septic Shock
    Interventions
    Daptomycin; determination of plasma concentration
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-01
    Completion
    2016-06
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSeptic Shock
    InterventionDaptomycin; determination of plasma concentration
    PhaseNot applicable
    Registry statusUnknown

  • Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury

    NCT02241941 · start 2014-09

    Registered record
    Registry ID
    NCT02241941
    Conditions
    Burn Injury
    Interventions
    Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2014-09
    Completion
    2016-10
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurn Injury
    InterventionDaptomycin
    PhasePhase 4
    Registry statusWithdrawn

  • Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia

    NCT01898338 · start 2013-12

    Registered record
    Registry ID
    NCT01898338
    Conditions
    Staph Aureus Methicillin Resistant Bacteremia
    Interventions
    Fosfomycin 2gr/6h iv; Daptomycin 10mg/kg/24h iv
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-12
    Completion
    2018-01-10
    Enrolment
    167

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaph Aureus Methicillin Resistant Bacteremia
    InterventionFosfomycin 2gr/6h iv; Daptomycin 10mg/kg/24h iv
    PhasePhase 3
    Registry statusCompleted

  • Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection

    NCT02000414 · start 2013-09

    Registered record
    Registry ID
    NCT02000414
    Conditions
    Peritoneal Infection
    Interventions
    intraperitoneal daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-09
    Completion
    2017-12
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeritoneal Infection
    Interventionintraperitoneal daptomycin
    PhaseNot applicable
    Registry statusCompleted

  • Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

    NCT01756924 · start 2012-12

    Registered record
    Registry ID
    NCT01756924
    Conditions
    Prosthetic Joint Infections of Hip; Prosthetic Joint Infections of Knee; Infected Spacers
    Interventions
    CEM-102; IV or Oral standard of care antibiotics; Rifampin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-12
    Completion
    2014-07
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProsthetic Joint Infections of Hip; Prosthetic Joint Infections of Knee; Infected Spacers
    InterventionCEM-102; IV or Oral standard of care antibiotics; Rifampin
    PhasePhase 2
    Registry statusTerminated

  • Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia

    NCT01515020 · start 2012-05

    Registered record
    Registry ID
    NCT01515020
    Conditions
    Nosocomial Infection; Healthcare-associated Infection
    Interventions
    vancomycin monotherapy; daptomycin monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-05
    Completion
    2014-07
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNosocomial Infection; Healthcare-associated Infection
    Interventionvancomycin monotherapy; daptomycin monotherapy
    PhasePhase 3
    Registry statusTerminated

  • Concentration of Antimicrobials in Catheter-lock Solutions

    NCT01592032 · start 2012-05

    Registered record
    Registry ID
    NCT01592032
    Conditions
    Catheter-Related Infections; Bacteremia.
    Interventions
    Vancomycin antimicrobial-lock solution; Teicoplanin antimicrobial-lock solution; Linezolid antimicrobial-lock solution; Daptomycin antimicrobial-lock solution; Tigecycline antimicrobial-lock solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-05
    Completion
    2015-12
    Enrolment
    125

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCatheter-Related Infections; Bacteremia.
    InterventionVancomycin antimicrobial-lock solution; Teicoplanin antimicrobial-lock solution; Linezolid antimicrobial-lock solution; Daptomycin antimicrobial-lock solution +1 more
    PhasePhase 4
    Registry statusUnknown

  • Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients

    NCT01734694 · start 2011-10

    Registered record
    Registry ID
    NCT01734694
    Conditions
    Health Care Associated Pneumonia; Osteomyelitis/Septic Arthritis; Endocarditis; Bacteremia; Acute Bacterial Skin and Skin Structure Infections
    Interventions
    Vancomycin; Ceftaroline; Daptomycin; Linezolid
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-10
    Completion
    2012-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealth Care Associated Pneumonia; Osteomyelitis/Septic Arthritis; Endocarditis; Bacteremia +1 more
    InterventionVancomycin; Ceftaroline; Daptomycin; Linezolid
    PhasePhase 4
    Registry statusTerminated

  • Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA

    NCT01419184 · start 2011-09-09

    Registered record
    Registry ID
    NCT01419184
    Conditions
    Staphylococcal Skin Infections
    Interventions
    Daptomycin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-09-09
    Completion
    2012-10-05
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Skin Infections
    InterventionDaptomycin; Vancomycin
    PhasePhase 4
    Registry statusCompleted

  • Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs)

    NCT01287832 · start 2011-06

    Registered record
    Registry ID
    NCT01287832
    Conditions
    Bacteremia
    Interventions
    Vancomycin; Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2011-06
    Completion
    2012-01
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacteremia
    InterventionVancomycin; Daptomycin
    PhasePhase 4
    Registry statusTerminated

  • Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)

    NCT01612052 · start 2011-05

    Registered record
    Registry ID
    NCT01612052
    Conditions
    MRSA - Methicillin Resistant Staphylococcus Aureus Infection
    Interventions
    Antibiotic Prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2011-05
    Completion
    2013-10
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMRSA - Methicillin Resistant Staphylococcus Aureus Infection
    InterventionAntibiotic Prophylaxis
    PhasePhase 4
    Registry statusUnknown

  • Daptomycin Versus Placebo in Patients With Neutropenia and Fever

    NCT01216241 · start 2011-04

    Registered record
    Registry ID
    NCT01216241
    Conditions
    Febrile Neutropenia
    Interventions
    Daptomycin; Saline Placebo; Daptomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-04
    Completion
    2013-04
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFebrile Neutropenia
    InterventionDaptomycin; Saline Placebo; Daptomycin
    PhasePhase 3
    Registry statusTerminated

  • Retrospective Evaluation of Safety and Efficacy of Daptomycin Used in Patients With Serious Gram-positive Infections

    NCT01314053 · start 2011-02

    Registered record
    Registry ID
    NCT01314053
    Conditions
    Serious Gram-positive Infections
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2011-02
    Completion
    2011-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSerious Gram-positive Infections
    InterventionNot recorded
    PhaseNot recorded
    Registry statusUnknown

  • Collect Clinical Data in Chinese Patients Received CUBICIN Treatment for Actual Usage in Clinical Practice

    NCT01212601 · start 2011-01

    Registered record
    Registry ID
    NCT01212601
    Conditions
    S. Aureus Bloodstream Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-01
    Completion
    2012-11
    Enrolment
    203

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionS. Aureus Bloodstream Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty

    NCT01196169 · start 2010-10

    Registered record
    Registry ID
    NCT01196169
    Conditions
    Staphylococcal Infections; Methicillin-resistant Staphylococcus Aureus
    Interventions
    Daptomycin; Vancomycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-10
    Completion
    2014-03
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStaphylococcal Infections; Methicillin-resistant Staphylococcus Aureus
    InterventionDaptomycin; Vancomycin
    PhasePhase 4
    Registry statusTerminated